Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 265-269

  Karlson, Björn W ^a,b   Nicholls, Stephen J ^c   Lundman, Pia ^d   Palmer, Mike K ^e   Barter, Philip J ^f  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^d DANDERYD HOSPITAL   (Sweden)

^e KEELE UNIVERSITY   (United Kingdom)

^f HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Atorvastatin; Guidelines; Low density lipoprotein cholesterol; Meta analysis; Rosuvastatin; Simvastatin; Targets

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

AGED; ATHEROSCLEROSIS; CHOLESTEROL, LDL; EUROPE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SIMVASTATIN; SULFONAMIDES;

EID: 84876805989     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.027     Document Type: Article

References (15)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
2. Rosensen R.S. Statins: can the new generation make an impression?. Expert Opin Emerg Drugs 2004, 9:269-279.
3. LaRosa J., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J Am Med Assoc 2001, 285:2486-2497.
6. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation 2004, 110:227-239.
7. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
8. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
9. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012, 19:585-667.
10. Conroy R.M., Pyörälä K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
11. Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010, 105:69-76.
12. Barter P.J., Brandrup-Wognsen G., Palmer M.K., Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 2010, 51:1546-1553.
13. Karlson B.W., Nicholls S.J., Lundman P., Barter P.J., Palmer M.K. Baseline LDL-C and choice and dose of statin as determinants of LDL-C goal achievement: meta-analysis from the VOYAGER database. Eur Heart J 2011, 32(Suppl. 1):342.
14. Kitkungvan D., Lynn Fillipon N.M., Dani S.S., Downey B.C. Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J Clin Lipidol 2010, 4:293-297.
15. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury June 8, 2011, US Food and Drug Administration, Available from:, [accessed 10.01.2013]. http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm.